PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 16,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health. For more information, visit www.ppdi.com.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ANGELINI PHARMA, INC. U.S. LAUNCHES FIRST INFECTION PREVENTION PORTFOLIO

PR Newswire | February 03, 2020

news image

Angelini Pharma Inc. U.S., an international healthcare company headquartered in Maryland, is tackling the epidemic of healthcare-acquired infections (HAIs) with their new line of infection prevention products. HAIs continue to cause preventable complications and poor patient outcomes. HAIs cause more patient deaths every year than breast, prostate, and colorectal cancer. With Angelini's new portfolio, designed to be used across the care continuum, they are addressing the "why" behi...

Read More

VIFOR PHARMA AND CARA THERAPEUTICS ANNOUNCES SIGN LICENSE AGREEMENT FOR IV KORSUVA™* TO TREAT DIALYSIS PATIENTS WITH PRURITUS

Vifor Pharma and Cara Therapeutics, Inc. | October 20, 2020

news image

Vifor Pharma and Cara Therapeutics, Inc. today announced that both companies have signed a license agreement for commercialization of Korsuva (difelikefalin) Injection (“IV Korsuva”) for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in the US dialysis market for non-Fresenius Medical Care clinics under a Cara 60%, Vifor Pharma 40% profit-sharing arrangement. “With an established fully dedicated nephrology sales force in the US, Vifor Pharma is an ideal co...

Read More

Pharmacy Market

FUSION PHARMACEUTICALS AND TRIUMF ANNOUNCE EXPANDED R&D COLLABORATION FOR ACTINIUM SUPPLY PRODUCTION

Fusion Pharmaceuticals Inc. | August 13, 2021

news image

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, and TRIUMF, Canada's particle accelerator centre, today announced that the companies have entered into the next phase of their collaboration agreement for the development, production, and supply of actinium-225. Fusion will provide to TRIUMF funding to further develop technology to produce actinium-225 and in return Fusion will have ...

Read More

Pharmacy Market

STEVANATO GROUP ANNOUNCES EXPANSION OF CORPORATE HEADQUARTERS

Stevanato Group | November 18, 2021

news image

Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the expansion of its corporate headquarters with the construction of a new facility in Piombino Dese, Italy to advance operations and growth of the Company. The new 6,750 square meter facility is expected to support the optimization of Stevanato Group’s industrial footprint, with about 2,500 square m...

Read More
news image

ANGELINI PHARMA, INC. U.S. LAUNCHES FIRST INFECTION PREVENTION PORTFOLIO

PR Newswire | February 03, 2020

Angelini Pharma Inc. U.S., an international healthcare company headquartered in Maryland, is tackling the epidemic of healthcare-acquired infections (HAIs) with their new line of infection prevention products. HAIs continue to cause preventable complications and poor patient outcomes. HAIs cause more patient deaths every year than breast, prostate, and colorectal cancer. With Angelini's new portfolio, designed to be used across the care continuum, they are addressing the "why" behi...

Read More
news image

VIFOR PHARMA AND CARA THERAPEUTICS ANNOUNCES SIGN LICENSE AGREEMENT FOR IV KORSUVA™* TO TREAT DIALYSIS PATIENTS WITH PRURITUS

Vifor Pharma and Cara Therapeutics, Inc. | October 20, 2020

Vifor Pharma and Cara Therapeutics, Inc. today announced that both companies have signed a license agreement for commercialization of Korsuva (difelikefalin) Injection (“IV Korsuva”) for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in the US dialysis market for non-Fresenius Medical Care clinics under a Cara 60%, Vifor Pharma 40% profit-sharing arrangement. “With an established fully dedicated nephrology sales force in the US, Vifor Pharma is an ideal co...

Read More
news image

Pharmacy Market

FUSION PHARMACEUTICALS AND TRIUMF ANNOUNCE EXPANDED R&D COLLABORATION FOR ACTINIUM SUPPLY PRODUCTION

Fusion Pharmaceuticals Inc. | August 13, 2021

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, and TRIUMF, Canada's particle accelerator centre, today announced that the companies have entered into the next phase of their collaboration agreement for the development, production, and supply of actinium-225. Fusion will provide to TRIUMF funding to further develop technology to produce actinium-225 and in return Fusion will have ...

Read More
news image

Pharmacy Market

STEVANATO GROUP ANNOUNCES EXPANSION OF CORPORATE HEADQUARTERS

Stevanato Group | November 18, 2021

Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the expansion of its corporate headquarters with the construction of a new facility in Piombino Dese, Italy to advance operations and growth of the Company. The new 6,750 square meter facility is expected to support the optimization of Stevanato Group’s industrial footprint, with about 2,500 square m...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us